Clinical trials: BRAIN MALIGNANCIES AFTER RADIATION THERAPY
Adult Ependymoblastoma, Adult Giant Cell Glioblastoma
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
This pilot phase I/II trial studies the side effects and best dose of plerixafor after radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed high grade glioma.
- Conditions
- Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT01977677
- Testing
- radiation therapy, temozolomide, plerixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lawrence Recht
CNS Malignancy
Cognitive Function After Treatment of Primary CNS Malignancy
In this study, the investigators propose to evaluate cognitive function and determine the feasibility of neurocognitive assessment using a select CogState test battery in patients with primary intracranial malignancies receiving…
- Trial name
- NCT03055364
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Mayo Clinic
Brain Tumor, Brain Necrosis
Development of MRF for Characterization of Brain Tumors After Radiotherapy
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short…
- Conditions
- Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
- Trial name
- NCT06101069
- Testing
- MRF in conjunction with IVIM MRI without contrast
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Primary Brain Tumour, Radiation Toxicity
Cognitive Function After Radiation Therapy for Primary Brain Tumours
This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction.
- Conditions
- Primary Brain Tumour, Radiation Toxicity, Cognitive Impairment
- Trial name
- NCT04306432
- Testing
- Cognitive tests and Patient Reported Outcomes
- Where
- 5 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Brain and Central Nervous System Tumors, Glioblastoma Multiforme
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112502
- Testing
- Celecoxib, Isotretinoin, Temozolomide
- Where
- 12 sites in United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor and may…
- Trial name
- NCT00047294
- Testing
- celecoxib, temozolomide, thalidomide
- Where
- 4 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Brain Metastases
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current…
- Trial name
- NCT04365374
- Testing
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
- Where
- 37 sites in United States
- Volunteers
- 230 people
- Sponsor
- GT Medical Technologies, Inc.
Brain Metastases, Growing Lesions After Radiosurgical Treatment
Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases
The purpose of this multicenter study is to assess a diagnostic strategy concerning differential diagnosis between radiation necrosis and relapse in brain metastases treated with radiosurgery.
- Trial name
- CV-METANEC (NCT02636634)
- Testing
- imaging
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Metastasis, Bladder Cancer
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
For patients who have one or two metastases in the brain, the tumor(s) can often be removed with surgery to relieve symptoms from the tumor(s) and to improve survival.
- Conditions
- Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer
- Trial name
- NCT00587964
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Carotid Artery Stenosis
Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy
The purpose of this research study is to understand how radiation therapy may affect blood vessels in the neck called the carotid arteries.
- Conditions
- Head and Neck Cancer, Carotid Artery Stenosis, Cardiovascular Complication
- Trial name
- NCT05490875
- Testing
- Carotid ultrasound, Blood draw, Survey
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Wake Forest University Health Sciences
Glioblastoma Multiforme, Anaplastic Astrocytoma
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
- Trial name
- NCT00089427
- Testing
- IL13-PE38QQR, Surgery for placement, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- INSYS Therapeutics Inc
Anaplastic Ependymoma, Brain Ependymoma
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
The primary aim of this randomized phase III trial was to study whether the addition of maintenance chemotherapy delivered after surgical resection and focal radiation would be better than surgery and focal radiation alone.
- Conditions
- Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma
- Trial name
- NCT01096368
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin
- Where
- 209 sites in United States, Australia and 2 more
- Volunteers
- 479 people
- Sponsor
- Children's Oncology Group
Brain Metastases, Adult
Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy
In advanced cancer disease brain metastases are common, difficult to treat, and are associated with a poor prognosis. As new local and systemic therapies are eventually resulting in improved survival and quality of life for…
- Trial name
- ESTRON (NCT03285932)
- Testing
- post-operative stereotactic radiosurgery (SRS), Whole brain radiotherapy (WBRT)
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- Juergen Debus
Brain Metastases, Radiosurgery
Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy.
- Trial name
- NCT05868928
- Testing
- Magnetic resonance imaging (MRI), Diffusion-weighted MRI, Arterial spin labeling (ASL)
- Where
- South Korea
- Volunteers
- 132 people
- Sponsor
- Asan Medical Center
Lung Cancer, Metastatic Cancer
Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery
RATIONALE: Steroid therapy, such as dexamethasone, may reduce swelling, pain, and other symptoms of inflammation and may be effective in treating some of the problems caused by cancer and cancer treatment.
- Trial name
- NCT00403065
- Testing
- dexamethasone, quality-of-life assessment, radiation therapy
- Where
- 70 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Medical Research Council
Brain Tumor, Head and Neck Cancer
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will…
- Trial name
- CogRT (NCT05658731)
- Testing
- substructure informed planning, Neurocognitive Testing, MRI
- Where
- 2 sites in United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
This phase II trial studies the effect of neuropsychological evaluation and intervention in maintaining quality of life after radiation therapy in patients with cancer that has spread to the brain (metastases).
- Trial name
- NCT05503251
- Testing
- Best Practice, Neuropsychological Assessment, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells.
- Trial name
- NCT00003484
- Testing
- carmustine, irinotecan hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Darell D. Bigner, MD, PhD
Brain Tumor
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues.
- Trial name
- MemoryRT (NCT07470606)
- Testing
- Memantine, Raloxifene
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
High-Grade Gliomas
Bevacizumab and Irinotecan to Treat Brain Tumors
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. It has shown activity against human brain tumors in laboratory tests and human clinical trials.
- Trial name
- NCT00393094
- Testing
- Bevacizumab, Irinotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)